(RTTNews) - Shares of Co-Diagnostics, Inc. (CODX) jumped 15% on Monday morning after the company announced it received FDA's emergency use authorization for its Covid-19 test.
CODX is currently trading at $27.49, up $3.49 or 14.55%, on the Nasdaq.
Co-Diagnostics said its partner, Clinical Reference Laboratory has FDA Emergency Use Authorization for CRL Rapid Response, a saliva-based COVID-19 test that can be self-administered at home, work or any other setting and then tested using Co-Diagnostics' patented CoPrimer technology.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
